Reintroduction of oxaliplatin: A viable approach to the long-term management of metastatic colorectal cancer

Oncology

Volumn 79, Issue 5-6, 2011, Pages 389-399

  Grothey, Axel ^a  

^a MAYO CLINIC   (United States)

Author keywords

Colorectal cancer; Neurotoxicity; Oxaliplatin; Palliative therapy; Reintroduction

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO;

CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; ORGANOPLATINUM COMPOUNDS;

EID: 79953040815     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323491     Document Type: Review

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-1425. (Pubitemid 39429665)
3. American Cancer Society: Cancer Facts and Figures 2006. Atlanta, American Cancer Society, 2007.
4. Sun W, Haller DG: The Saltz article reviewed. Oncology (Williston Park) 2005; 19: 1158-1160. (Pubitemid 350042578)
5. Goldberg RM, Rothenberg ML, van Cutsem E, Benson ABI, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12: 38-50. (Pubitemid 46143501)
6. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069. (Pubitemid 46606353)
7. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes- Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, De Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947. (Pubitemid 30644117)
8. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Cholet P, Llory JF, Letourneau Y, Coudert B, Bertheault-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Lévi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147. (Pubitemid 30036347)
9. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W, Buechele T, Schmoll HJ: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24 h 5-FU infusion/ FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002; 21:(abstract No. 512).
10. Grothey A: Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30(suppl 15):5-13. (Pubitemid 37259547)
11. Mitchell PL, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Thomson JA, Clarke S: Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006; 6: 146-151. (Pubitemid 44445750)
12. Gamelin L, Boisdron-Celle M, Morel A, Poirier AL, Berger V, Gamelin E, Tournigand C, de Gramont A: Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-1189.
13. Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS: Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 2008; 26(suppl).
14. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol, in press.
15. Cassidy J, Bjarnason GA, Hickish T, Topham C, Provencio M, Bodoky G, Landherr L, Koralewski P, Lopez-Vivanco G: Randomized double blind (DM) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral neuropathy (PSN) induced by oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in 1st line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol 2006; 24(suppl 18S).
16. Grothey A: Clinical management of oxaliplatin- associated neurotoxicity. Clin Colorectal Cancer 2005; 5(suppl 1):S38-S46.
17. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour MT, Topham C, McArdle C, Cain D, Stephens RJ: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003; 361: 457-464. (Pubitemid 36173710)
18. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30. (Pubitemid 41095110)
19. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680.
20. Saif MW, Reardon J: Management of oxaliplatin- induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1: 249-258.
21. Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Louvet C, De Gramont A: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 2007; 25(suppl).
22. Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M: Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. Chemotherapy 2008; 54: 395-403.
23. Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G: FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006; 70: 345-350. (Pubitemid 46074943)
24. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez- Staub N, Louvet C, Andre T, Tabah-Fisch I, De Gramont A: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: a GERCOR study. J Clin Oncol 2006; 24: 394-400. (Pubitemid 46630458)
25. Adams R, Wilson R, Seymour MT, Meade AM, Madi A, Cassidy J, Fisher D, Kenny S, Kaplan R, Maughan TS: Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN). Eur J Cancer Suppl 2009; 7: 10.
26. De Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez- Staub N, Louvet C, Andre T, Tabah-Fisch I, Tournigand C: Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 3224-3229. (Pubitemid 47325605)
27. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572.
28. Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M, Barcelo R, Cervantes A, Andre T, Colin P, Louvet C, De Gramont A: FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 2007; 110: 2666-2671. (Pubitemid 350250335)
29. Bidard F, Bengrine L, Figer A, Cervantes A, André T, Lledo G, Mabro M, Tournigand C, Louvet C, De Gramont A: Efficacy of FOLFIRI3 (irinotecan 100 mg/m 2 D1, D3 combined with LV5FU) or other irinotecanbased regimens in oxaliplatin-pretreated metastatic colorectal cancer in the OPTIMOX1 study. J Clin Oncol 2008; 26(suppl).
30. Maughan T, Adams RA, Smith CG, Seymour MT, Wilson R, Meade AM, Fisher D, Madi A, Cheadle J, Kaplan R: Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wildtype advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN). Eur J Cancer Suppl 2009; 7: 4.
31. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, De Gramont A: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009; 27: 5727-5733.
32. Tabernero J, Aranda E, Gomez A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont M, Diaz-Rubio E: Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent BEV as maintenance therapy in patients with metastatic colorectal cancer: the MACRO trial (Spanish Cooperative Group for the Treatment of Digestive Tumors). J Clin Oncol 2010; 28(suppl 15s):abstract 3501.
33. de Gramont Lesparre AH, Chibaudel B, Bourges O, Perez-Staub N, Tournigand C, Maindrault-Goebel F, André T, Larsen AK, Afchain P, Louvet C: Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin- based therapy. J Clin Oncol 2009; 27(suppl):15s.
34. Chibaudel B, Tournigand C, Perez-Staub N, Bourges O, Maindrault-Goebel F, André T, Lledo G, Louvet C, Bonnetain F, De Gramont A: Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC). J Clin Oncol 2009; 27(suppl):15s.